This problem of treatment resistance calls for further research into alternative medications. Due to emerging antibiotic resistance and poor patient compliance with finishing the treatment cycle, which lowers H. pylori elimination rates, H. pylori infection has grown extremely resistant to conventional first-line treatment regimens. As a result, there is a lot of interest in evaluating novel antibiotic combinations and therapy plans for H. pylori.‎
The antibiotic nitazoxanide (NTZ), which has been stabilised as a treatment, has microbiological properties that are comparable to those of metronidazole. It has a broad spectrum of action against microbial and anaerobic bacteria, anaerobic protozoa, and parasitic worms .
Inhibition of lipid polysaccharide (LS) caused by the production of pro-inflammatory cytokines in macrophages are additional noteworthy immune properties of nitazoxanide .
When NTZ and omeprazole were combined (1 g of NTZ twice daily with 20 milligrammes of omeprazole once daily) for seven days, 91 patients experienced an 83% eradication rate. 
All this points to the importance of further research on nitazoxanide based treatment regimens as novel regimens for Helicobacter pylori eradication as this may solve the puzzle of increasing resistance of Helicobacter pylori to conventional treatment.